Loading
Cancer, Hypoxia, and Metabolism / Head and Neck Cancer Studies / Salivary Gland Disorders and Functions · Journal article
Discover Oncology · July 16, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a discovery study combining transcriptomic profiling and functional genomic screening that identifies ALDOA and PGK1 as metabolic dependencies in oral squamous cell carcinoma, with associations between elevated expression and poor survival in TCGA data. Genetic inhibition of these targets suppressed glycolytic activity and tumor growth in cell and xenograft models, and dual targeting showed synergistic effects, but no clinical trial evidence supports therapeutic efficacy in patients.
Integrated computational discovery study with functional validation: LASSO prognostic signature derivation from TCGA, CRISPR-Cas9 dependency screening, and mechanistic studies in cell lines and xenografts. TCGA-OSCC cohort for transcriptomic analysis; OSCC cell lines for in vitro studies; xenograft models for in vivo validation. Intervention: Genetic silencing (CRISPR or knockdown) of ALDOA or PGK1; pharmacologic inhibition with Aldometanib (ALDOA inhibitor) and CBR-470-1 (PGK1 inhibitor); combined dual targeting. Compared with: Monotherapy; wildtype or control cell lines and xenografts.
Elevated ALDOA and PGK1 expression significantly associated with poor patient survival in TCGA-OSCC cohort Genetic silencing of ALDOA or PGK1 reduced extracellular acidification rates (ECAR) and suppressed tumor cell proliferation in vitro and in vivo Combined targeting showed synergy by Bliss independence analysis; Aldometanib (ALDOA inhibitor) and CBR-470-1 (PGK1 inhibitor) produced greater tumor suppression than monotherapy in xenograft models
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest ALDOA and PGK1 warrant further investigation as therapeutic targets in OSCC, but results remain preclinical and mechanistic. Clinical trial data in OSCC patients are needed before any therapeutic recommendation can be made.
Integrative computational and functional study identifying candidate biomarkers and therapeutic targets with in vitro and xenograft evidence, but no clinical trial data supporting clinical utility or efficacy in patients.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest ALDOA and PGK1 warrant further investigation as therapeutic targets in OSCC, but results remain preclinical and mechanistic. Clinical trial data in OSCC patients are needed before any therapeutic recommendation can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Oral squamous cell carcinoma (OSCC) is associated with high mortality and limited effective targeted therapies. Although metabolic reprogramming is closely linked to malignancy, the key metabolic regulators that functionally drive OSCC progression and may serve as therapeutic targets remain incompletely defined. METHODS: We combined clinical transcriptomic analysis with functional genomic screening to identify metabolic vulnerabilities in OSCC. A Least Absolute Shrinkage and Selection Operator (LASSO)-derived prognostic gene signature was constructed using transcriptomic data from The Cancer Genome Atlas (TCGA)-OSCC cohort. To prioritize functionally critical targets, gene essentiality and tumor selectivity were evaluated using large-scale CRISPR-Cas9 dependency data from the Cancer Dependency Map (DepMap) project. RESULTS: This analysis identified Aldolase A (ALDOA) and Phosphoglycerate Kinase 1 (PGK1) as candidate targets with prognostic relevance and strong dependency across OSCC cell lines. Elevated expression of ALDOA and PGK1 was significantly associated with poor patient survival. Mechanistically, genetic silencing of ALDOA or PGK1 impaired glycolytic activity, as evidenced by reduced extracellular acidification rates (ECAR), and suppressed tumor cell proliferation in vitro and in vivo. Furthermore, combined targeting of these two glycolytic enzymes produced synergistic anti-tumor effects. Bliss independence analysis showed synergy between the ALDOA inhibitor Aldometanib and the PGK1 inhibitor CBR-470-1, and the combination produced greater tumor suppression than either monotherapy in xenograft models. CONCLUSION: Our findings indicate that ALDOA and PGK1 contribute to metabolic reprogramming and poor prognosis in OSCC. These findings support further evaluation of dual ALDOA and PGK1 inhibition as a potential therapeutic strategy for OSCC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.